{"id":617606,"date":"2026-10-10T05:15:32","date_gmt":"2026-10-10T05:15:32","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/617606\/volta-peptides-wins-research-peptide-supplier-of-the-year-2026-award-from-peptide-atlas.html"},"modified":"2026-10-10T05:15:32","modified_gmt":"2026-10-10T05:15:32","slug":"volta-peptides-wins-research-peptide-supplier-of-the-year-2026-award-from-peptide-atlas","status":"publish","type":"post","link":"https:\/\/www.pennsylvania-magazine.com\/news\/story\/617606\/volta-peptides-wins-research-peptide-supplier-of-the-year-2026-award-from-peptide-atlas.html","title":{"rendered":"Volta Peptides Wins Research Peptide Supplier of the Year 2026 Award from Peptide Atlas"},"content":{"rendered":"
\n
\"Volta<\/a><\/div>\n
\n
Volta Peptides announces its Peptide Vendor of the Year 2026 award from Peptide Atlas. The announcement graphic features the Volta Peptides logo, a gold 2026 panel and the company\u2019s website, voltapeptides.com.<\/div>\n<\/div>\n<\/div>\n
Volta Peptides, a Canadian research peptide supplier shipping from British Columbia, has received the Peptide Supplier of the Year 2026 award from Peptide Atlas. The company holds a 4.9\/5 community rating on the platform and provides independent third-party testing, batch-specific Certificates of Analysis and publicly accessible laboratory records.<\/div>\n

BRITISH COLUMBIA, Canada – October 10, 2026 –<\/strong> Volta Peptides, a leading oligopeptide research institution and supplier of research-grade peptides, announced that it has received the Peptide Vendor of the Year 2026 award from Peptide Atlas, a peptide research reference and vendor assessment platform.<\/p>\n

Volta Peptides supplies laboratory research compounds through voltapeptides.com<\/a>, with orders dispatched from British Columbia to Canadian and international destinations. The company combines a greater-than-99% HPLC purity specification with batch-specific testing documentation and a publicly accessible Certificate of Analysis archive.<\/p>\n

Peptide Atlas Lists a 4.9\/5 Community Rating<\/strong><\/p>\n

As of October 8, 2026, Peptide Atlas’s Volta Peptides profile displays a community rating of 4.9 out of 5 from 1,850 reviews. The profile also records the supplier’s Canadian operations, published testing documentation, publicly available pricing and research-use-only policy.<\/p>\n

Volta Peptides stood out when it came to customer service, product quality, testing rigorousness and standards, and competitive prices.<\/p>\n

Readers can view the Volta Peptides vendor profile on Peptide Atlas<\/a>.<\/p>\n

Public Testing Records Support Batch Transparency<\/strong><\/p>\n

Volta Peptides’ quality assurance archive provides Certificates of Analysis with laboratory verification links, lot identifiers, analytical methods and measured results. Published SideChain Analytics reports include HPLC-MS\/MS testing for compound identity, chromatographic purity and net peptide content.<\/p>\n

Examples in the archive include BPC-157 10 mg<\/a>, batch VPBP10100, with reported chromatographic purity of 99.9%; Retatrutide 20 mg<\/a>, batch VPRT20100, at 99.7%; and GHK-Cu 100 mg<\/a>, batch VPGC100100, at 99.8%.<\/p>\n

These measurements apply to the specific samples tested. Researchers can compare the batch identifier associated with their product against the corresponding laboratory report rather than relying solely on a general purity claim.<\/p>\n

The reports are publicly accessible through Volta’s quality assurance and Certificate of Analysis archive.<\/p>\n

Research Peptides Shipped from British Columbia<\/strong><\/p>\n

Volta’s provide compounds to researchers and institutions such as: 5-Amino-1MQ 10 mg, BPC-157 5 mg, BPC-157 10 mg, Cagrilintide 5 mg, CJC-1295 No DAC + Ipamorelin 10 mg (5 mg + 5 mg), DSIP 10 mg, Epithalon 10 mg, GHK-Cu 50 mg, GHK-Cu 100 mg, GHRP-2 5 mg, GHRP-6 5 mg, HCG 5,000 IU, Ipamorelin 5 mg, KLOW 80 mg, KPV 10 mg, Melanotan II 10 mg, MOTS-C 10 mg, Retatrutide 10 mg, Retatrutide 20 mg, Semaglutide 10 mg, Semaglutide 20 mg, Sermorelin 10 mg, SS-31 10 mg, TB-500 10 mg, Tesamorelin 10 mg, Tirzepatide 10 mg, Tirzepatide 30 mg.<\/p>\n

The company offers domestic Canadian fulfillment, international shipping and wholesale ordering, alongside educational resources and research calculation tools. Current specifications and availability are published in the Volta Peptides research catalog.<\/p>\n

Products are supplied exclusively for in vitro laboratory research and are not intended for human consumption, veterinary use or diagnostic applications.<\/p>\n

About Volta Peptides<\/strong><\/p>\n

Volta Peptides is a Canadian research peptide supplier shipping from British Columbia. The company emphasizes independent analytical testing, batch-specific Certificates of Analysis, accessible quality documentation and responsive customer support. Learn more at voltapeptides.com.<\/p>\n

About Peptide Atlas<\/strong><\/p>\n

Peptide Atlas is a peptide research reference platform featuring compound evidence profiles, vendor listings, laboratory assay records and educational resources. Its methodology distinguishes the strength of scientific evidence for compounds from the records used to assess suppliers. Learn more at peptideatlas.co.<\/p>\n

Media enquiries:<\/p>\n

Volta Peptides<\/p>\n

team@voltapeptides.com<\/p>\n

https:\/\/voltapeptides.com\/contact<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Volta Peptides Ltd<\/a>
Contact Person:<\/strong> Johnathan Maurino
Email:<\/strong> Send Email<\/a>
Country:<\/strong> Canada
Website:<\/strong> voltapeptides.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Volta Peptides announces its Peptide Vendor of the Year 2026 award from Peptide Atlas. The announcement graphic features the Volta Peptides logo, a gold 2026 panel and the company\u2019s website,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/617606"}],"collection":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/comments?post=617606"}],"version-history":[{"count":0,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/617606\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/media?parent=617606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/categories?post=617606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/tags?post=617606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}